The role of bone marrow biopsy and FDG‐PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non‐Hodgkin B‐cell lymphoma and Hodgkin lymphoma. accuracy in a multicenter series of 372 patients. Issue 8 (28th May 2015)

• Record Type: Journal Article
• Authors: Chen‐Liang, Tzu‐Hua; Martin‐Santos, Taida; Jerez, Andres; Senent, Leonor; Orero, Maria Teresa; Remigia, Maria Jose; Muiña, Begoña; Romera, Marta; Fernandez–Muñoz, Hermogenes; Raya, Jose M.; Fernandez‐Gonzalez, Marta; Lancharro, Aima; Villegas, Carolina; Carlos Herrera, Juan; Frutos, Laura; Luis Navarro, Jose; Uña, Jon; Igua, Carolina; Sanchez‐Vaño, Raquel; Cozar, Maria del Puig; Contreras, Jose; Sanchez‐Blanco, Jose Javier; Perez‐Ceballos, Elena; Ortuño, Francisco Jose
• Is Part Of: American journal of hematology. Volume 90:Issue 8(2015:Aug.)
• Page Start: 686
• Page End: 690
• Publication Date: 2015-05-28
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24044
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Bone marrow infiltration (BMI), categorized as an extra‐nodal site, affects stage and is associated with poor prognosis in newly diagnosed lymphoma patients. We have evaluated the accuracy of PET/CT and bone marrow biopsy (BMB) to assess BMI in 372 lymphoma patients [140 Hodgkin Lymphoma (HL) and 232 High Grade B‐cell non‐Hodgkin Lymphoma (HG B‐NHL), among them 155 Diffuse Large B‐Cell Lymphoma (DLCL)]. For HL cases, and taking into account PET/CT, sensitivity, negative predictive value (NPV) and accuracy were 96.7, 99.3, and 99.3% while those of BMB were 32.3, 83.8, and 85%, respectively. For HG B‐NHL and considering PET/CT, sensitivity, NPV, and accuracy were 52.7, 81.7, and 84.1%, while those of BMB were 77.6, 90.2, and 90.7%, respectively. In the HG B‐NHL group, 25 patients would have been under‐staged without BMB. These results lead us to recommend PET/CT and the avoidance of BMB to assess BMI in HL. In the case of HG B‐NHL, bone marrow status should be assessed firstly by means of PET/CT; only in either focal or diffuse PET/CT with low borderline SUV max values or in negative cases, should BMB be carried out afterwards. In the HG B‐NHL setting and at the present moment, both techniques are complementary. Am. J. Hematol. 90:686–690, 2015. © 2015 Wiley Periodicals, Inc.</p> </abstract>